Raymond James Financial
ACET icon

Raymond James Financial’s Adicet Bio ACET Stock Holding History

Raymond James Financial’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-829
Closed -$10.7K – 5157
2025
Q3 		$10.7K Buy
829
+594
+253% +$7K ﹤0.01% 4934
2025
Q2 		$2.29K Buy
+235
New +$2.48K ﹤0.01% 6378

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Raymond James Financial's ACET Position: Q4 2025 in Review

Raymond James Financial sold out of Adicet Bio (ACET) in Q4 2025, closing a stake of 829 shares — an estimated $10.7K sold.

Raymond James Financial first reported a position in ACET in Q2 2025 and held it in 2 quarters. The position peaked at $10.7K in Q3 2025. 49 funds tracked by Wall St. Rank hold ACET as of Q4 2025.

  • Raymond James Financial reported no remaining Adicet Bio position as of Q4 2025 after selling out during the quarter.
  • Raymond James Financial sold 829 Adicet Bio shares in Q4 2025, an estimated $10.7K.
  • Raymond James Financial first reported a position in Adicet Bio in Q2 2025 and held it in 2 quarters.
  • Raymond James Financial's Adicet Bio position peaked at $10.7K in Q3 2025.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2025.

Based on Raymond James Financial's 13F filing for Q4 2025, filed 18 Feb 2026.